$499.7 13.9 2.9%
Last Trade - 05/03/21
| Market Cap | £30.84bn |
| Enterprise Value | £31.22bn |
| Revenue | £1.96bn |
| Position in Universe | 278th / 6651 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,602 | 1,775 | 1,969 | 2,213 | 2,407 | 2,707 | 3,055 | 3,384 | +11.1% | ||
| +17.9 | +15.6 | +34.4 | +31.2 | +13.4 | +37.8 | +9.73 | +17.4 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | December 19, 1983 |
| Public Since | June 21, 1991 |
| No. of Shareholders: | 395 |
| No. of Employees: | 9,300 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 85,426,080 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1 Idexx Dr, WESTBROOK, 04092-2041, United States |
| Web | https://www.idexx.com/ |
| Phone | +1 207 5560300 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
As of 05/03/21, shares in IDEXX Laboratories Inc are trading at $499.7, giving the company a market capitalisation of £30.84bn. This share price information is delayed by 15 minutes.
Shares in IDEXX Laboratories Inc are currently trading at $499.7 and the price has moved by 95.84% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the IDEXX Laboratories Inc price has moved by 54.47% over the past year.
Of the analysts with advisory recommendations for IDEXX Laboratories Inc, there are there are currently 4 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for IDEXX Laboratories Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
IDEXX Laboratories Inc is scheduled to issue upcoming financial results on the following dates:
IDEXX Laboratories Inc does not currently pay a dividend.
IDEXX Laboratories Inc does not currently pay a dividend.
IDEXX Laboratories Inc does not currently pay a dividend.
To buy shares in IDEXX Laboratories Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in IDEXX Laboratories Inc are currently trading at $499.7, giving the company a market capitalisation of £30.84bn.
Here are the trading details for IDEXX Laboratories Inc:
Based on an overall assessment of its quality, value and momentum, IDEXX Laboratories Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in IDEXX Laboratories Inc are currently priced at $499.7. At that level they are trading at 7.86% discount to the analyst consensus target price of 0.00.
Analysts covering IDEXX Laboratories Inc currently have a consensus Earnings Per Share (EPS) forecast of 7.389 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IDEXX Laboratories Inc. Over the past six months, the relative strength of its shares against the market has been 19.19%. At the current price of $499.7, shares in IDEXX Laboratories Inc are trading at 20.27% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The IDEXX Laboratories Inc PE ratio based on its reported earnings over the past 12 months is 74.21. The shares are currently trading at $499.7.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
IDEXX Laboratories Inc's management team is headed by:
Here are the top five shareholders of IDEXX Laboratories Inc based on the size of their shareholding:
